mesenchymal stem cell adipocyte differentiation medium Search Results


90
ATCC mesenchymal stem cells hmsc
Mesenchymal Stem Cells Hmsc, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mesenchymal+stem+cell+adipocyte+differentiation+medium/Penicillium+oxalicum+Currie+et+Thom/us10415054-105-41-36
Average 90 stars, based on 1 article reviews
mesenchymal stem cells hmsc - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
AbMole Bioscience mesenchymal stem cells complete culture medium kit
Mesenchymal Stem Cells Complete Culture Medium Kit, supplied by AbMole Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mesenchymal+stem+cell+adipocyte+differentiation+medium/mesenchymal+stem+cells+complete+culture+medium+kit/10__2147_slash_dmso__s262950-46-5-23
Average 90 stars, based on 1 article reviews
mesenchymal stem cells complete culture medium kit - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
ZenBio full-term human placentas
Full Term Human Placentas, supplied by ZenBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mesenchymal+stem+cell+adipocyte+differentiation+medium/full+term+human+placentas/pm40658893-367-1-10
Average 90 stars, based on 1 article reviews
full-term human placentas - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

99
Bio-Techne corporation human mesenchymal stem cell functional identification kit
Human Mesenchymal Stem Cell Functional Identification Kit, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mesenchymal+stem+cell+adipocyte+differentiation+medium/Human+Mesenchymal+Stem+Cell+Functional+Identification+Kit/bio-techne+corporation___sc006
Average 99 stars, based on 1 article reviews
human mesenchymal stem cell functional identification kit - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

90
Biochrom 30 polyamine protocol
Characterization of the bone and osteoblast pathology. A . Photograph of the bone biopsy. B . Steady state SMS mRNA levels relative to GAPDH expression in cultured fibroblasts and osteoblasts. The patient’s cells did not differ significantly from controls. Data were derived by qRT-PCR analysis of 3 independent extractions of total RNA. C . Immunoblot showing steady state SMS protein expression in patient and control osteoblasts. ß-tubulin is shown as a loading control. D . Graph showing steady state SMS protein levels in the patient and control <t>hBMSCs</t> relative to ß-tubulin levels; there was no significant difference. The data are based on 3 independent experiments for each cell line. E - J . Immunofluorescent detection of SMS protein subcellular distribution in unaffected (E-G) and Patient II-1 (H-J) hBMSCs. SMS protein is shown in red and the nucleus is shown in blue. K . Graph quantifying immunoblot detected steady state SMS protein levels in the cytoplasm and nuclei of patient and control hBMSCs. The cytoplasmic expression was normalized to β-tubulin expression and the nuclear expression to p84 expression. L . Polyamine quantification in fibroblasts and osteoblasts. Note that the patient hBMSCs have a more striking imbalance of spermidine <t>and</t> <t>spermine</t> levels than do the patient fibroblasts, * p < 0.05, *** p < 0.005. M . Osteogenic potential of bone marrow stromal cells (hBMSCs) isolated from Patient II-1 sample is markedly lower than that of an unaffected control (cnt). The hBMSCs were seeded in triplicates (6x10 4 /12-well) and either kept untreated (-) or treated (+) with osteogenic differentiation media (see ) for 18 days. After the treatment, cells were fixed and were stained with Alizarin Red S to check for calcium deposition, a marker of osteogenic differentiation.
30 Polyamine Protocol, supplied by Biochrom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mesenchymal+stem+cell+adipocyte+differentiation+medium/30+polyamine+protocol/pmc04428506-42-9-19
Average 90 stars, based on 1 article reviews
30 polyamine protocol - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc stemdiff mesenchymal progenitor kit
Characterization of the bone and osteoblast pathology. A . Photograph of the bone biopsy. B . Steady state SMS mRNA levels relative to GAPDH expression in cultured fibroblasts and osteoblasts. The patient’s cells did not differ significantly from controls. Data were derived by qRT-PCR analysis of 3 independent extractions of total RNA. C . Immunoblot showing steady state SMS protein expression in patient and control osteoblasts. ß-tubulin is shown as a loading control. D . Graph showing steady state SMS protein levels in the patient and control <t>hBMSCs</t> relative to ß-tubulin levels; there was no significant difference. The data are based on 3 independent experiments for each cell line. E - J . Immunofluorescent detection of SMS protein subcellular distribution in unaffected (E-G) and Patient II-1 (H-J) hBMSCs. SMS protein is shown in red and the nucleus is shown in blue. K . Graph quantifying immunoblot detected steady state SMS protein levels in the cytoplasm and nuclei of patient and control hBMSCs. The cytoplasmic expression was normalized to β-tubulin expression and the nuclear expression to p84 expression. L . Polyamine quantification in fibroblasts and osteoblasts. Note that the patient hBMSCs have a more striking imbalance of spermidine <t>and</t> <t>spermine</t> levels than do the patient fibroblasts, * p < 0.05, *** p < 0.005. M . Osteogenic potential of bone marrow stromal cells (hBMSCs) isolated from Patient II-1 sample is markedly lower than that of an unaffected control (cnt). The hBMSCs were seeded in triplicates (6x10 4 /12-well) and either kept untreated (-) or treated (+) with osteogenic differentiation media (see ) for 18 days. After the treatment, cells were fixed and were stained with Alizarin Red S to check for calcium deposition, a marker of osteogenic differentiation.
Stemdiff Mesenchymal Progenitor Kit, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mesenchymal+stem+cell+adipocyte+differentiation+medium/stemdiff+mesenchymal+progenitor+kit/pm39367925-378-7-11
Average 90 stars, based on 1 article reviews
stemdiff mesenchymal progenitor kit - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
NeuroRepair bone marrow stromal cells
Effects of <t>BMSCs</t> treatment on the number of TH, NeuN, and GFAP positive cells in SN, and DA and its metabolites in striatum at 4 weeks after dMCAO. (A) Representative microphotographs of immunohistochemistry for TH (II,VI,X) , NeuN (III,VII,XI) , and GFAP (IV,VIII,XII) in SN. The pictures on the right are magnified from the square area on the left. Scale bar: I, V, IX, 250 μm; II–IV, VI–VIII, X–XII, 50 μm. (B) Quantitative analyses of TH, NeuN, GFAP-positive cells in the SNc at 1 and 4 weeks after dMCAO. Transplantation of BMSCs increased the numbers of TH + [ F (2, 60) = 31.51, p < 0.01] and NeuN + cells [ F (2, 78) = 17.20, p < 0.01], and decreased the number of GFAP + cells [ F (2, 78) = 1848.10, p < 0.01] in the ipsilateral SNc after dMCAO. Each bar represents the mean ± S.D. * p < 0.05 vs. sham-operated group, # p < 0.05 vs. contralateral groups at the same time point and & p < 0.05 vs. ipsilateral vehicle groups ( n = 6 in each group). (C) The DA (I) , DOPAC (II) , and HVA (III) concentrations in striata at 1 and 4 weeks after dMCAO with or without BMSCs transplantation. Transplantation with BMSCs increased the concentration of DA [ F (2, 8) = 6.33, p < 0.05] in the ipsilateral striatum after dMCAO, maintained the concentration of DOPAC [ F (2, 11) = 0.53, p > 0.05] and HVA [ F (2, 11) = 0.67, p > 0.05] in the ipsilateral striatum after dMCAO. Each bar represents the mean ± SD * p < 0.05 vs. sham-operated group and # p < 0.05 vs. contralateral groups at the same time point and & p < 0.05 vs. ipsilateral vehicle groups ( n = 4 in each group). SN, substantia nigra; SNc, substantia nigra compact part; TH, tyrosine hydroxylase; NeuN, neuron-specific nuclear-binding protein; GFAP, Glial fibrillary acidic protein; Sham, sham-operated; BMSCs, bone marrow stromal cells; DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; con, contralateral; ip, ipsilateral; w, week; dMCAO, distal middle cerebral artery occlusion.
Bone Marrow Stromal Cells, supplied by NeuroRepair, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mesenchymal+stem+cell+adipocyte+differentiation+medium/bone+marrow+stromal+cells/pmc06668054-23-5-11
Average 90 stars, based on 1 article reviews
bone marrow stromal cells - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
ZenBio bone marrow-derived mesenchymal stem cells (bm-mscs)
Patents Related to the Diagnostic and Therapeutic Application of Exosomes Towards Bone Disorders
Bone Marrow Derived Mesenchymal Stem Cells (Bm Mscs), supplied by ZenBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mesenchymal+stem+cell+adipocyte+differentiation+medium/bone+marrow+derived+mesenchymal+stem+cells++bm+mscs+/pmc08149288-8-0-14
Average 90 stars, based on 1 article reviews
bone marrow-derived mesenchymal stem cells (bm-mscs) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Schmid GmbH human lung mesenchymal stem cell-conditioned medium
Patents Related to the Diagnostic and Therapeutic Application of Exosomes Towards Bone Disorders
Human Lung Mesenchymal Stem Cell Conditioned Medium, supplied by Schmid GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mesenchymal+stem+cell+adipocyte+differentiation+medium/human+lung+mesenchymal+stem+cell+conditioned+medium/10__1093_slash_icvts_slash_ivs561-34-1-23
Average 90 stars, based on 1 article reviews
human lung mesenchymal stem cell-conditioned medium - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
AstraZeneca ltd allogeneic mesenchymal stem cells
Patents Related to the Diagnostic and Therapeutic Application of Exosomes Towards Bone Disorders
Allogeneic Mesenchymal Stem Cells, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mesenchymal+stem+cell+adipocyte+differentiation+medium/allogeneic+mesenchymal+stem+cells/10__2337_slash_db12___2323___2568-865-8-3
Average 90 stars, based on 1 article reviews
allogeneic mesenchymal stem cells - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
ScienCell mesenchymal stem cell growth supplement (mscgs)
Patents Related to the Diagnostic and Therapeutic Application of Exosomes Towards Bone Disorders
Mesenchymal Stem Cell Growth Supplement (Mscgs), supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mesenchymal+stem+cell+adipocyte+differentiation+medium/mesenchymal+stem+cell+growth+supplement/10__1016_slash_j__polymertesting__2023__108109-87-17-9
Average 90 stars, based on 1 article reviews
mesenchymal stem cell growth supplement (mscgs) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc stemdiff mesoderm induction medium
Patents Related to the Diagnostic and Therapeutic Application of Exosomes Towards Bone Disorders
Stemdiff Mesoderm Induction Medium, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mesenchymal+stem+cell+adipocyte+differentiation+medium/stemdiff+mesoderm+induction+medium/pmc05425621__mmc1-49-5-9
Average 90 stars, based on 1 article reviews
stemdiff mesoderm induction medium - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Characterization of the bone and osteoblast pathology. A . Photograph of the bone biopsy. B . Steady state SMS mRNA levels relative to GAPDH expression in cultured fibroblasts and osteoblasts. The patient’s cells did not differ significantly from controls. Data were derived by qRT-PCR analysis of 3 independent extractions of total RNA. C . Immunoblot showing steady state SMS protein expression in patient and control osteoblasts. ß-tubulin is shown as a loading control. D . Graph showing steady state SMS protein levels in the patient and control hBMSCs relative to ß-tubulin levels; there was no significant difference. The data are based on 3 independent experiments for each cell line. E - J . Immunofluorescent detection of SMS protein subcellular distribution in unaffected (E-G) and Patient II-1 (H-J) hBMSCs. SMS protein is shown in red and the nucleus is shown in blue. K . Graph quantifying immunoblot detected steady state SMS protein levels in the cytoplasm and nuclei of patient and control hBMSCs. The cytoplasmic expression was normalized to β-tubulin expression and the nuclear expression to p84 expression. L . Polyamine quantification in fibroblasts and osteoblasts. Note that the patient hBMSCs have a more striking imbalance of spermidine and spermine levels than do the patient fibroblasts, * p < 0.05, *** p < 0.005. M . Osteogenic potential of bone marrow stromal cells (hBMSCs) isolated from Patient II-1 sample is markedly lower than that of an unaffected control (cnt). The hBMSCs were seeded in triplicates (6x10 4 /12-well) and either kept untreated (-) or treated (+) with osteogenic differentiation media (see ) for 18 days. After the treatment, cells were fixed and were stained with Alizarin Red S to check for calcium deposition, a marker of osteogenic differentiation.

Journal: Orphanet Journal of Rare Diseases

Article Title: Impaired osteoblast and osteoclast function characterize the osteoporosis of Snyder - Robinson syndrome

doi: 10.1186/s13023-015-0235-8

Figure Lengend Snippet: Characterization of the bone and osteoblast pathology. A . Photograph of the bone biopsy. B . Steady state SMS mRNA levels relative to GAPDH expression in cultured fibroblasts and osteoblasts. The patient’s cells did not differ significantly from controls. Data were derived by qRT-PCR analysis of 3 independent extractions of total RNA. C . Immunoblot showing steady state SMS protein expression in patient and control osteoblasts. ß-tubulin is shown as a loading control. D . Graph showing steady state SMS protein levels in the patient and control hBMSCs relative to ß-tubulin levels; there was no significant difference. The data are based on 3 independent experiments for each cell line. E - J . Immunofluorescent detection of SMS protein subcellular distribution in unaffected (E-G) and Patient II-1 (H-J) hBMSCs. SMS protein is shown in red and the nucleus is shown in blue. K . Graph quantifying immunoblot detected steady state SMS protein levels in the cytoplasm and nuclei of patient and control hBMSCs. The cytoplasmic expression was normalized to β-tubulin expression and the nuclear expression to p84 expression. L . Polyamine quantification in fibroblasts and osteoblasts. Note that the patient hBMSCs have a more striking imbalance of spermidine and spermine levels than do the patient fibroblasts, * p < 0.05, *** p < 0.005. M . Osteogenic potential of bone marrow stromal cells (hBMSCs) isolated from Patient II-1 sample is markedly lower than that of an unaffected control (cnt). The hBMSCs were seeded in triplicates (6x10 4 /12-well) and either kept untreated (-) or treated (+) with osteogenic differentiation media (see ) for 18 days. After the treatment, cells were fixed and were stained with Alizarin Red S to check for calcium deposition, a marker of osteogenic differentiation.

Article Snippet: We also measured spermine and spermidine levels in cultured human bone marrow stromal cells (hBMSCs) and fibroblasts using the Biochrom 30 polyamine protocol and assessed the osteogenic potential of hBMSCs.

Techniques: Expressing, Cell Culture, Derivative Assay, Quantitative RT-PCR, Western Blot, Control, Isolation, Staining, Marker

Effects of BMSCs treatment on the number of TH, NeuN, and GFAP positive cells in SN, and DA and its metabolites in striatum at 4 weeks after dMCAO. (A) Representative microphotographs of immunohistochemistry for TH (II,VI,X) , NeuN (III,VII,XI) , and GFAP (IV,VIII,XII) in SN. The pictures on the right are magnified from the square area on the left. Scale bar: I, V, IX, 250 μm; II–IV, VI–VIII, X–XII, 50 μm. (B) Quantitative analyses of TH, NeuN, GFAP-positive cells in the SNc at 1 and 4 weeks after dMCAO. Transplantation of BMSCs increased the numbers of TH + [ F (2, 60) = 31.51, p < 0.01] and NeuN + cells [ F (2, 78) = 17.20, p < 0.01], and decreased the number of GFAP + cells [ F (2, 78) = 1848.10, p < 0.01] in the ipsilateral SNc after dMCAO. Each bar represents the mean ± S.D. * p < 0.05 vs. sham-operated group, # p < 0.05 vs. contralateral groups at the same time point and & p < 0.05 vs. ipsilateral vehicle groups ( n = 6 in each group). (C) The DA (I) , DOPAC (II) , and HVA (III) concentrations in striata at 1 and 4 weeks after dMCAO with or without BMSCs transplantation. Transplantation with BMSCs increased the concentration of DA [ F (2, 8) = 6.33, p < 0.05] in the ipsilateral striatum after dMCAO, maintained the concentration of DOPAC [ F (2, 11) = 0.53, p > 0.05] and HVA [ F (2, 11) = 0.67, p > 0.05] in the ipsilateral striatum after dMCAO. Each bar represents the mean ± SD * p < 0.05 vs. sham-operated group and # p < 0.05 vs. contralateral groups at the same time point and & p < 0.05 vs. ipsilateral vehicle groups ( n = 4 in each group). SN, substantia nigra; SNc, substantia nigra compact part; TH, tyrosine hydroxylase; NeuN, neuron-specific nuclear-binding protein; GFAP, Glial fibrillary acidic protein; Sham, sham-operated; BMSCs, bone marrow stromal cells; DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; con, contralateral; ip, ipsilateral; w, week; dMCAO, distal middle cerebral artery occlusion.

Journal: Frontiers in Cellular Neuroscience

Article Title: Bone Marrow Stromal Cells Alleviate Secondary Damage in the Substantia Nigra After Focal Cerebral Infarction in Rats

doi: 10.3389/fncel.2019.00338

Figure Lengend Snippet: Effects of BMSCs treatment on the number of TH, NeuN, and GFAP positive cells in SN, and DA and its metabolites in striatum at 4 weeks after dMCAO. (A) Representative microphotographs of immunohistochemistry for TH (II,VI,X) , NeuN (III,VII,XI) , and GFAP (IV,VIII,XII) in SN. The pictures on the right are magnified from the square area on the left. Scale bar: I, V, IX, 250 μm; II–IV, VI–VIII, X–XII, 50 μm. (B) Quantitative analyses of TH, NeuN, GFAP-positive cells in the SNc at 1 and 4 weeks after dMCAO. Transplantation of BMSCs increased the numbers of TH + [ F (2, 60) = 31.51, p < 0.01] and NeuN + cells [ F (2, 78) = 17.20, p < 0.01], and decreased the number of GFAP + cells [ F (2, 78) = 1848.10, p < 0.01] in the ipsilateral SNc after dMCAO. Each bar represents the mean ± S.D. * p < 0.05 vs. sham-operated group, # p < 0.05 vs. contralateral groups at the same time point and & p < 0.05 vs. ipsilateral vehicle groups ( n = 6 in each group). (C) The DA (I) , DOPAC (II) , and HVA (III) concentrations in striata at 1 and 4 weeks after dMCAO with or without BMSCs transplantation. Transplantation with BMSCs increased the concentration of DA [ F (2, 8) = 6.33, p < 0.05] in the ipsilateral striatum after dMCAO, maintained the concentration of DOPAC [ F (2, 11) = 0.53, p > 0.05] and HVA [ F (2, 11) = 0.67, p > 0.05] in the ipsilateral striatum after dMCAO. Each bar represents the mean ± SD * p < 0.05 vs. sham-operated group and # p < 0.05 vs. contralateral groups at the same time point and & p < 0.05 vs. ipsilateral vehicle groups ( n = 4 in each group). SN, substantia nigra; SNc, substantia nigra compact part; TH, tyrosine hydroxylase; NeuN, neuron-specific nuclear-binding protein; GFAP, Glial fibrillary acidic protein; Sham, sham-operated; BMSCs, bone marrow stromal cells; DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; con, contralateral; ip, ipsilateral; w, week; dMCAO, distal middle cerebral artery occlusion.

Article Snippet: Over the past two decades, bone marrow stromal cells (BMSCs) based neurorepair has emerged as a promising therapeutic strategy for ischemic stroke.

Techniques: Immunohistochemistry, Transplantation Assay, Concentration Assay, Binding Assay

Cortico-striatum-nigral tract retrograde tracing with PRV-152. (A) PRV-152 was injected into the ipsilateral SNr. Regions of interest (ROI) of PRV-152 positive cell counting were shown. Dark shaded area represents ischemic region after dMCAO; lighter shaded area represents ROI. (B) Schematic illustration of the fluorescent signal of PRV-152 in sham-operated and dMCAO groups with or without BMSCs transplantation after PRV-152 was injected into the ipsilateral SNr. (C) Representative photographs of fluorescent double staining of PRV-152 (green) and DAPI (blue) in the ipsilateral cortex (I–IV) , striatum (V–VIII) and SNr (IX-XII) at 4 days after PRV-152 injection in sham-operated group. (D) Representative photographs of fluorescent double staining of PRV-152 (green) and DAPI (blue) in the ipsilateral cortex (I–IV) , striatum (V–VIII) , and SNr (IX–XII) at 4 weeks after PRV-152 injection in vehicle group. (E) Representative photographs of fluorescent double staining of PRV-152 (green) and DAPI (blue) in the ipsilateral cortex (I–IV) , striatum (V–VIII) and SNr (IX–XII) at 4 weeks after PRV-152 injection in BMSCs group. Scale bar, 50 μm. (F) Quantitative analyses of PRV-152 + cell number in the ipsilateral cortex, striatum and SNr after dMCAO. Transplantation with BMSCs increased PRV-152 + cells in the ipsilateral cortex [ F (2, 19) = 9.85, p < 0.01], striatum [ F (2, 41) = 10.67, p < 0.01] and SNr [ F (2, 19) = 6.05, p < 0.01] after dMCAO. Each bar represents the mean ± SD * p < 0.05 vs. sham-operated group and # p < 0.05 vs. vehicle group ( n = 7 in each group). SNr, substantia nigra pars reticulata; Cor, cortex; Str, striatum; PRV, pseudorabies virus; Sham, sham-operated; w, week; dMCAO, distal middle cerebral artery occlusion; BMSCs, bone marrow stromal cells; DAPI, 4’, 6- diamidino-2-phenylindole.

Journal: Frontiers in Cellular Neuroscience

Article Title: Bone Marrow Stromal Cells Alleviate Secondary Damage in the Substantia Nigra After Focal Cerebral Infarction in Rats

doi: 10.3389/fncel.2019.00338

Figure Lengend Snippet: Cortico-striatum-nigral tract retrograde tracing with PRV-152. (A) PRV-152 was injected into the ipsilateral SNr. Regions of interest (ROI) of PRV-152 positive cell counting were shown. Dark shaded area represents ischemic region after dMCAO; lighter shaded area represents ROI. (B) Schematic illustration of the fluorescent signal of PRV-152 in sham-operated and dMCAO groups with or without BMSCs transplantation after PRV-152 was injected into the ipsilateral SNr. (C) Representative photographs of fluorescent double staining of PRV-152 (green) and DAPI (blue) in the ipsilateral cortex (I–IV) , striatum (V–VIII) and SNr (IX-XII) at 4 days after PRV-152 injection in sham-operated group. (D) Representative photographs of fluorescent double staining of PRV-152 (green) and DAPI (blue) in the ipsilateral cortex (I–IV) , striatum (V–VIII) , and SNr (IX–XII) at 4 weeks after PRV-152 injection in vehicle group. (E) Representative photographs of fluorescent double staining of PRV-152 (green) and DAPI (blue) in the ipsilateral cortex (I–IV) , striatum (V–VIII) and SNr (IX–XII) at 4 weeks after PRV-152 injection in BMSCs group. Scale bar, 50 μm. (F) Quantitative analyses of PRV-152 + cell number in the ipsilateral cortex, striatum and SNr after dMCAO. Transplantation with BMSCs increased PRV-152 + cells in the ipsilateral cortex [ F (2, 19) = 9.85, p < 0.01], striatum [ F (2, 41) = 10.67, p < 0.01] and SNr [ F (2, 19) = 6.05, p < 0.01] after dMCAO. Each bar represents the mean ± SD * p < 0.05 vs. sham-operated group and # p < 0.05 vs. vehicle group ( n = 7 in each group). SNr, substantia nigra pars reticulata; Cor, cortex; Str, striatum; PRV, pseudorabies virus; Sham, sham-operated; w, week; dMCAO, distal middle cerebral artery occlusion; BMSCs, bone marrow stromal cells; DAPI, 4’, 6- diamidino-2-phenylindole.

Article Snippet: Over the past two decades, bone marrow stromal cells (BMSCs) based neurorepair has emerged as a promising therapeutic strategy for ischemic stroke.

Techniques: Retrograde Tracing, Injection, Cell Counting, Transplantation Assay, Double Staining, Virus

Patents Related to the Diagnostic and Therapeutic Application of Exosomes Towards Bone Disorders

Journal: International Journal of Nanomedicine

Article Title: Drug Delivery to the Bone Microenvironment Mediated by Exosomes: An Axiom or Enigma

doi: 10.2147/IJN.S307843

Figure Lengend Snippet: Patents Related to the Diagnostic and Therapeutic Application of Exosomes Towards Bone Disorders

Article Snippet: Bone marrow-derived mesenchymal stem cells (BM-MSCs) and Adipose-derived stem cells (ASCs) , WO2019139762A1 , Zen-Bio, Inc. (US) , Exosome compositions and use thereof for joint disorders and diseases , Filed on 2018/Status pending.

Techniques: Diagnostic Assay, Biomarker Discovery, Derivative Assay, CRISPR, Isolation, Injection, Clinical Proteomics